La Jolla Institute for Allergy and Immunology has elected three new board members:
A Heron Therapeutics postoperative pain anesthetic hit clinical trial targets in two additional areas, sending the company’s stock soaring.
San Diego-based Crinetics Pharmaceuticals, focused on endocrine-related cancers and endocrine disorders, appointed Alan Krasner as chief medical officer.
Sharp Mary Birch Hospital for Women & Newborns was awarded a $2.9 million grant to lead a multi-hospital, international study on a technique to increase the flow of blood from the umbilical cord into the infant’s circulatory system.
Boston-based Vertex Pharmaceuticals has opened a 170,000-square-foot research facility in San Diego, more than doubling the company’s footprint locally.
MEDICINE: High Volume a Must; Adoption Becoming Norm
In San Diego hospitals, robots are on the rise, judging by splashy marketing and an increase in robotic surgery cases, per data obtained by the San Diego Business Journal.
Damien McDevitt has joined Carlsbad’s Ionis Pharmaceuticals as chief business officer.
What does SleepScore Labs have in common with Portugal and Real Madrid? They all have Cristiano Ronaldo working for them.
A new UC San Diego center is targeting an unmet need: parasitic infections hurting poor and underserved communities.
A shareholder of San Diego-based biotech Senomyx is pushing for the company’s chairman to resign, an immediate company sale and a new board seat.
The San Diego/Imperial Chapter of the Alzheimer’s Association awarded a three-year, $175,000 fellowship to a UC San Diego researcher on a quest to determine the earliest indications of Alzheimer’s disease.
PHARMA: They’re Part of Growing Biotech Relationship
In San Diego, the last decade gave rise to biotechs farming out work to contract research organizations, or CROs. It’s an industry increasingly colored by China.
San Diego biotech Metacrine, which is working on drugs for liver, metabolic and gastrointestinal diseases, last week closed a $65 million Series C round.
San Diego biotech Trovagene closed an $18 million public offering on June 12.